Prostanoid F receptors elicit an inotropic effect in rat left ventricle by enhancing myosin light chain phosphorylation

Jon Riise1,2, Cam H.T. Nguyen1,2, Eirik Qvigstad1,2, Dagny L. Sandnes1, Jan-Bjørn Osnes1,2, Tor Skomedal1,2, Finn Olav Levy1,2*, and Kurt A. Krobert1,2

1Department of Pharmacology, University of Oslo, Sognsvannsv. 20, Building A2/A3, PO Box 1057 Blindern, N-0316 Oslo, Norway; and 2Center for Heart Failure Research, University of Oslo, 0407 Oslo, Norway

Received 26 October 2007; revised 28 June 2008; accepted 29 July 2008; online publish-ahead-of-print 14 August 2008

Aims The aims of this study were to determine if the prostanoid F receptor (FPR)-mediated inotropic effect in rat ventricle is mediated by increased phosphorylation of myosin light chain-2 (MLC-2) and to elucidate the signalling pathway(s) activated by FPRs to regulate MLC-2 phosphorylation.

Methods and results Contractility was measured in left ventricular strips from adult male rats. Strips were also snap-frozen, and changes in the phosphorylation level of both MLC-2 and myosin phosphatase targeting subunit-2 (MYPT-2) were quantified. FPR stimulation with fluprostenol increased contractility by ~100% above basal and increased phosphorylation of both MLC-2 (by ~30%) and MYPT-2 (by ~50%). The FPR-mediated inotropic effect and MLC-2 phosphorylation were reduced by a similar magnitude in the presence of the myosin light chain kinase (MLCK) inhibitor ML-7 (~60–70%) and an inhibitor of Ca2+/calmodulin, W-7 (~35%). Inhibition of Rho-associated kinase by Y-27632 reduced the FPR-mediated inotropic effect and MLC-2 phosphorylation by ~40–45% and MYPT-2 phosphorylation by ~70%. ML-7 and Y-27632 together reduced contractility and MLC-2 phosphorylation by ~70–80%. The FPR-mediated inotropic effect was only modestly affected by high concentrations of the inositol tris-phosphate (IP3) receptor blocker 2-APB, but not by the protein kinase C (PKC) inhibitor bisindolylmaleimide.

Conclusion The FPR-evoked inotropic effect is mediated by increasing the phosphorylation of MLC-2 through regulation of both MLCK and myosin light chain phosphatase activities. The second messenger IP3 and PKC are unlikely to be involved in the signalling cascade of the FPR-mediated positive inotropic effect. Therefore, FPR signalling mechanism(s) regulating MLC-2 phosphorylation likely extend beyond those classically established for Gq/11-coupled receptors.

KEYWORDS
Contractile function; Inotropic agents; Signal transduction; Ventricular function; Calcium sensitization

1. Introduction
Prostaglandins mediate a wide array of effects in different tissues. In heart, prostaglandins have effects upon inflammation and cardiomyocyte hypertrophy. Prostaglandins have been shown to elicit inotropic effects in myocardium of various species. In human heart, prostacyclin increases cardiac output, but it is difficult to establish if this is a direct effect, or an effect of increased sympathetic drive secondary to the vasodilatory effect of prostacyclin. In rat ventricle, stimulation of the FPR evokes a marked inotropic effect.

The cardiac inotropic effects of Gq/11-coupled receptors, such as the a1-adrenoceptor (a1-AR), 5-HT2A receptor, and endothelin-1 receptor, occur at least partly through myofilament Ca2+ sensitization by increased phosphorylation of MLC-2. In smooth and cardiac muscle, the level of MLC-2 phosphorylation is regulated through both Ca2+/calmodulin-dependent activation of myosin light chain kinase (MLCK) and Rho-associated kinase (ROCK)-mediated inhibition of myosin light chain phosphatase (MLCP).

Stimulation of the Gq/11-Coupled FPR was reported to elicit an inotropic effect in rat left ventricle and increase levels of the second messengers IP3 and diacylglycerol (DAG). Although several mechanisms have been proposed, the mechanism underlying the FPR-mediated inotropic effect remains unknown.

Since the FPR is coupled to Gq/11 as is the a1-AR, it seems likely that FPR stimulation utilizes the same mechanism of enhancing MLC-2 phosphorylation for inotropic support. Increased phosphorylation of myosin light chain enhances Ca2+ sensitivity of the myofilaments in vascular smooth muscle during PGF2α-evoked contractions. Therefore, the primary objective of these studies was to determine if increasing MLC-2 phosphorylation was a requisite for FPR-mediated inotropic effects. We also wanted to determine...
if both MLCK and MLCP activities could be regulated by FPR stimulation. Lastly, we evaluated the role of the classical $G_{o,11}$-coupled second messengers DAG and IP$_3$.

Our data show that the FPR stimulation increases MLC-2 phosphorylation through both activating MLCK and inhibiting MLCP. The classical second messengers of $G_{o,11}$-coupled receptors are unlikely signalling candidates for the FPR-mediated inotropic effect.

2. Materials and methods

2.1 Animals

Animal care was according to the Norwegian Animal Welfare Act, which conforms to the European Convention for the protection of Vertebrate animals used for Experimental and other Scientific Purposes (Council of Europe no. 123, Strasbourg 1985) and were approved by the Norwegian National Animal Research Committee. Male Wistar rats of approximately 250–350 g were anesthetized (2–3% isoflurane in air) and subsequently euthanized, and the hearts were harvested.

2.2 Isolated papillary muscles and ventricular strips

Left ventricular strips and posterior papillary muscles were prepared and the contraction-relaxation cycles recorded and analysed as described previously.18 Maximal development of force ([dF/dt]$_{max}$) was measured and inotropic responses to agonists were expressed by increases in ([dF/dt]$_{max}$). The descriptive parameters at the end of the equilibration period were used as basal (control) values. The experiments were performed in the presence of blockers (added 90 min prior to agonist) of adrenergic (prazosin 1 $\mu$M, timolol 1 $\mu$C to prevent the aggregation of the actin 25) and 29 $\mu$C to prevent the aggregation of the actin

2.3 Sample preparations

Frozen tissue samples (10–20 mg) were homogenized in 700 $\mu$L ice-cold buffer containing 10% trichloroacetic acid, 90% acetone, 10 mM dithiothreitol (DTT) and phosphatase inhibitors (20 mM NaF and 0.1 mM calyculin A). The resulting homogenate with the precipitated proteins was mixed with an equal volume of cold 1 M KCl and incubated for 10 min at 4°C to prevent the aggregation of the actin and myosin myofilaments. In our experience, this step results in a more equal loading of protein amongst the samples. The homogenate was then centrifuged (20000 g, 4°C, 10 min) and washed twice with acetone containing 10 mM DTT, 0.1 mM calyculin A, and 20 mM NaF. The vacuum dried pellets were dissolved in ice-cold urea sample buffer at pH 8.6 at room temperature (8 M urea, 20 mM Tris–HCl, 22 mM glycine, and 10 mM DTT). The samples were then sonicated on ice and left for 2 h at 4°C while being rotated. The sonication step was repeated. The samples were sheared through ice-cold needles before they were spun down for 1 min (20 000 g at 4°C). Total protein concentration of tissue homogenate supernatant was determined according to Bradford, and the samples were diluted with urea sample buffer to equalize total protein between samples. The positive inotropic response elicited by fluprostenol (100 nM) was 102% of its own control value (non-stimulated). In studies conducted in the presence of inhibitors, the effect of fluprostenol upon MLC-2 phosphorylation was reported as relative changes to the percent change relative to the inhibitor alone in ventricular strips taken from the same heart.

2.4 MLC-2 phosphorylation

The level of MLC-2 phosphorylation was analysed using glycerol polyacrylamide gel electrophoresis (40% glycerol/12.5% acrylamide) separating proteins by charge-to-mass ratio. This method separates the phosphorylated and non-phosphorylated MLC-2 on the same gel, allowing simultaneous probing of phosphorylated and total MLC-2. The gels were pre-run for 90 min at 100 V before sample application (6 $\mu$g/lane) and then run for 90 min at 100 V and 100 min at 500 V. The proteins were blotted to polyvinylidene difluoride (PVDF) membranes, blocked with 5% non-fat dry milk in phosphate buffered saline with 0.05% Tween-20, and hybridized with mouse anti-ventricular MLC-2 monovalent antibody (Cat 1150-S, 1:1000, GE Healthcare), followed by a horseradish peroxidase-conjugated secondary anti-mouse antibody (GE Healthcare). Protein bands were visualized by chemiluminescence and quantified by densitometry. The data are reported as phosphorylated MLC-2 in percent of total MLC-2. The effect of fluprostenol in the presence of inhibitors was calculated as the percent change relative to the inhibitor alone in ventricular strips taken from the same heart.

2.5 MYPT-2 phosphorylation

MYPT-2 phosphorylation was determined by 6% SDS–polyacrylamide gel electrophoresis (SDS–PAGE), separating proteins based on size. After electrophoresis, proteins (6.75 $\mu$g/lane) were blotted onto a PVDF membrane, blocked with 5% non-fat dry milk in phosphate-buffered saline with 0.05% Tween-20, and incubated with anti-phospho MYPT recognizing Thr696 of rat MYPT-1 and a corresponding site on rat MYPT-2 (Cat 07-251, 1:2000, Upstate) followed by a horseradish peroxidase-linked secondary antibody (GE Healthcare) and visualization by chemiluminescence using a UCP Sensisam (UVP Inc., CA, USA). Membranes incubated initially with anti-phospho MYPT antibody were stripped with 0.5 M NaOH-re-blocked and re-probed with anti-MYPT-1/MYPT-2 (Cat 1488-1, 1:4000, Epitomics) for the determination of total MYPT. Changes in MYPT-2 phosphorylation were reported as relative changes to its own control value (non-stimulated). In studies conducted in the presence of inhibitors, the effect of fluprostenol upon MYPT-2 phosphorylation in the presence of inhibitors was calculated according to the following formula and reported as the percentage of the effect of fluprostenol in the absence of inhibitors: fluprostenol in the presence of the inhibitor/inhibitor alone)/(fluprostenol alone/no drug).

2.6 Statistics

Data are expressed as mean ± SEM from n animals. P < 0.05 was considered statistically significant (student’s t-test and ANOVA). When appropriate, Bonferroni corrections were made to control for multiple comparisons.

3. Results

3.1 FPR stimulation elicits a large inotropic effect qualitatively similar to $\alpha_1$-AR stimulation

FPR stimulation with the selective agonist fluprostenol first induced a small transient negative, followed by a large and sustained positive, inotropic response similar to phenylephrine stimulation of the $\alpha_1$-AR (Figure 1A and B). The transient negative inotropic component was 11 ± 1% (n = 25) and 29 ± 2% (n = 23) below basal for FPR and $\alpha_1$-AR, respectively. The maximal positive inotropic response evoked by fluprostenol (100 nM) was 102 ± 4% (n = 30) above basal and 67 ± 5% (n = 23) for phenylephrine (100 $\mu$M) (Figure 1C). The positive inotropic response elicited by fluprostenol and phenylephrine, approximated 75
and 49%, respectively, of the maximal inotropic effect of 10 μM isoproterenol (139 ± 9% above basal, n = 12) (Figure 1C). Fluprostenol concentration–response curves without and with 3.9 μM or 11.1 μM of the FPR antagonist AL-8810 were nearly parallel with –logEC50 (M) values of 8.7 ± 0.1, 8.1 ± 0.1 and 7.6 ± 0.1, respectively (Figure 2). The inhibition constant (Kb) calculated for AL-8810 was 1.0–1.3 μM (pKb = 6.0–5.9), consistent with the reported affinity of AL-8810 at FPRs in vascular smooth muscle cells.21 Concentrations of AL-8810 up to 10 μM are selective for the FPR.21 The positive inotropic response evoked by 100 nM fluprostenol is likely through FPR activation due to its high selectivity for FPR.22 AL-8810 caused no significant change in basal or maximal fluprostenol-induced positive inotropic response (42 ± 6% above baseline without and 36 ± 3% with AL-8810). The lower maximal positive inotropic response in these experiments compared to a single concentration (100 nM fluprostenol) likely reflects desensitization. The maximal positive inotropic response evoked by phenylephrine did not differ significantly between a single saturating concentration and that obtained in concentration–response curves (66 ± 4.5 vs. 59.5 ± 3.8% above baseline).

3.2 Characteristics of the contraction–relaxation cycle

The contraction–relaxation cycle was not shortened by fluprostenol or phenylephrine indicating a lack of a lusitropic effect (Figures 1A and B, inset graphs). As expected, β-adrenergic receptor stimulation with isoproterenol produced a large lusitropic effect [reduced time to peak force (TPF) and relaxation time (RT)], a characteristic of activation of the cAMP/PKA pathway (Figure 1D).18 The lack of a lusitropic effect of fluprostenol is shared with agonists acting on Gq-coupled receptors such as the α1-adrenergic and 5-HT2A serotonin receptors.12,18

3.3 FPR stimulation increases phosphorylation of MLC-2 and MYPT-2

In the absence of agonist stimulation (basal) 21.0 ± 0.8% (n = 19) of the total MLC-2 was phosphorylated. Fluprostenol (100 nM) increased the percentage of MLC-2 phosphorylated to 27.4 ± 1.0% (n = 19), representing a 29.4% increase in phosphorylated MLC-2 above basal (Figure 3A and B). Fluprostenol (100 nM) increased MYPT-2 phosphorylation by 49 ± 6% above basal (n = 18; Figure 3A and B). The absolute
3.4 Effect of myosin light chain kinase inhibition

MLCK inhibition attenuates the α1-AR inotropic effect and phosphorylation of MLC-2 in rat heart.10 Thus, we hypothesized that FPR activation enhanced MLC-2 phosphorylation through similar mechanisms. The selective MLCK inhibitor ML-7 (20 μM) significantly reduced the FPR-mediated inotropic effect by ~70% [35 ± 4% (n = 9) above basal with ML-7 vs. 102 ± 5% (n = 30) without; P < 0.05] (Figure 4A). ML-7 reduced basal contractility by 15 ± 4% (n = 19). ML-7 reduced the fluprostenol-induced increase of MLC-2 phosphorylation by 57 ± 5% (Figure 4B). Phosphorylation of MYPT-2 trended lower (~18% decrease), but was not significantly reduced by ML-7 (Figure 4F). These data indicate that FPR-stimulated activation of MLCK contributes to both enhanced MLC-2 phosphorylation and the inotropic effect.

3.5 Effect of calmodulin inhibition

The Ca2+–binding protein calmodulin (CaM) activates MLCK in smooth muscle, inducing contraction through enhancing MLC phosphorylation.14 Therefore, we evaluated the effect of inhibiting CaM (with 50 μM W-7) upon the FPR-mediated inotropic effect. In the presence of W-7, the fluprostenol-induced inotropic effect was reduced by ~33% [69 ± 5% above basal with W-7 (n = 10) vs. 102 ± 5% without (n = 30); P < 0.05; Figure 4A]. W-7 reduced basal contractility by 17 ± 1% (n = 20). W-7 reduced the fluprostenol-induced increase of MLC-2 phosphorylation by 35 ± 10% (Figure 4C). Phosphorylation of MYPT-2 was not affected by W-7 (Figure 4F). These data suggest a possible role for CaM in the activation of MLCK.

3.6 Effect of Rho-associated kinase inhibition

ROCK inhibition attenuates the α1-AR inotropic effect in rat heart.10 The phosphorylation status of MLC-2 is regulated by both MLCK and MLCP.14 The ability of MLCP to dephosphorylate MLC-2 is decreased by ROCK-mediated phosphorylation of MYPT.23 Therefore, we evaluated the effect of the ROCK inhibitor Y-27632 upon the FPR-mediated effects. Inhibition of ROCK by Y-27632 (50 μM) significantly reduced the FPR-mediated inotropic effect by ~45% [46 ± 4% above basal with Y-27632 (n = 12) vs. 102 ± 5% without (n = 30); P < 0.05; Figure 4A]. Y-27632 reduced basal contractility by 17 ± 2% (n = 22). Y-27632 reduced the fluprostenol-induced increase of MLC-2 phosphorylation by 40 ± 9% (Figure 4D). Phosphorylation of MYPT-2 was reduced by ~72% by Y-27632.

Figure 2 Concentration–response curves for fluprostenol in left ventricular papillary muscles or strips without (n = 10) or in the presence of 3.9 μM (n = 8) or 11 μM AL-8810 (n = 4). The inotropic responses are expressed in percent of maximum in each experiment. All pEC50 values were significantly different (P < 0.05).

Figure 3 (A) Western blots from glycerol (top panel) and SDS (middle and lower panel) polyacrylamide gels showing that fluprostenol stimulation (100 nM for ~10 min) increased phosphorylation of both MLC-2 and MYPT-2 in left ventricular strips. Western blots were probed with antibodies recognizing either MLC-2v (top panel), total MYPT-2 (middle panel) or phosphorylated MYPT1/2 (lower panel). (B) Fluprostenol (100 nM)-stimulated increase in the phosphorylation of MLC-2 and MYPT-2 reported as percent increase above the basal phosphorylation level. The amount of phosphorylated MLC-2 and MYPT-2 was quantified by measuring the density of the bands. Phosphorylated MLC-2 was expressed as percent of total MLC-2. The absolute phosphorylation level for MYPT-2 as a percentage of total MYPT-2 cannot be determined since estimates of non-phosphorylated and phosphorylated MYPT-2 levels were done separately.
The inhibition profile of Y-27632 indicates that the phosphatase is also involved, i.e. decreased MLCP activity likely contributes to the increased phosphorylation of MLC-2 and subsequent inotropic effect of FPR stimulation.

3.7 Effect of simultaneous inhibition of MLCK and ROCK activity

We evaluated the effect of blocking both MLCK and ROCK activity simultaneously. In the presence of both ML-7 (20 μM) and Y-27632 (50 μM), the fluprostenol-induced inotropic effect was reduced by ~89% [10 ± 3% above basal with both inhibitors (n = 13) vs. 102 ± 5% (n = 30) without inhibitors, Figure 4A], a significantly larger decrease compared with ML-7 alone (~70%). Combining ML-7 and Y-27632 further reduced the fluprostenol-induced increase of MLC-2 phosphorylation by 70 ± 9% compared to the effect of either ML-7 (57 ± 5%) or Y-27632 (40 ± 9%) alone (Figures 4B, D, and E). In the presence of both W-7 (50 μM) and Y-27632 (50 μM), the fluprostenol-induced inotropic effect was reduced by ~64% [38 ± 5% above basal with both inhibitors (n = 13) vs. 102 ± 5% (n = 30) without inhibitors, Figure 4A], a lesser decrease than observed after combining ML-7 and Y-27632. Combining W-7 and Y-27632 further reduced the fluprostenol-induced increase of MLC-2 phosphorylation (55 ± 8%) although the effect was not significantly different from Y-27632 (40 ± 9%) alone (Figures 4B, D, and E). Basal contractility was

![Figure 4](https://academic.oup.com/cardiovascres/article-abstract/80/3/407/323325/407)
reduced by ~26% in the combined presence of ML-7 and Y-27632 and by ~33% in the combined presence of W-7 and Y-27632, slightly greater reductions than by ML-7 or Y-27632 alone (15 and 17%, respectively). These data further support that both MLCK and MLCP are involved in the FPR-mediated increase of MLC-2 phosphorylation.

3.8 Effects of inhibiting the Gq second messengers DAG and IP3

The FPR signals through Gq,24 and FPR stimulation in rat ventricular cardiomyocytes increases the formation of IP3 and DAG.8 Their role in mediating the FPR inotropic effect, however, remains unknown. Therefore, we evaluated the effects of inhibiting the downstream targets of IP3 and DAG, the IP3 receptor and PKC, respectively. The FPR-mediated inotropic effect was slightly, but significantly reduced (~23%) in the presence of the IP3 receptor blocker 2-aminoethoxydiphenylborate (2-APB; 20 μM) (76 ± 4% above basal with 2-APB vs. 99 ± 7% without, n = 9; P < 0.05; Figure 5A). Although 20 μM 2-APB produced a modest, but significant rightward shift (∼0.2 log unit) in the concentration–response curve of fluprostenol, the shift was not significantly greater than that produced by 2 μM 2-APB (Figure 5B). The maximum positive inotropic response developed in the concentration–response experiments was not significantly different between the three groups (42.6 ± 4.9% and 50.2 ± 4.3% above basal with 2 μM and 20 μM 2-APB, respectively, and 44.4 ± 4% without inhibitors). Basal contractility was reduced by ~17% in the presence of 2-APB. The α1-AR-mediated inotropic effect was also attenuated by 2-APB by a similar magnitude (23 ± 11%; n = 9). To determine if activation of CaM is dependent upon Ca2+ released from IP3 receptor sensitive intracellular stores, we evaluated the effect of blocking simultaneously the IP3 receptor by 2-APB and CalM directly by W-7. The fluprostenol-induced inotropic effect was reduced by 57 ± 6% when combining W-7 and 2-APB, a value significantly greater than the individual effect of each inhibitor and similar to the sum of the individual effects of W-7 and 2-APB that is 62 ± 5%. These data indicate that the inhibitory effect of 2-APB occurs independently of the activation of CaM, reducing the likelihood that CaM is dependent upon IP3 receptor-mediated Ca2+ release. The non-selective PKC inhibitor bisindolylmaleimide (BIM) abolished the transient negative inotropic effect of fluprostenol or phenylephrine, as previously found for the 5-HT2A receptor.12 However, BIM did not reduce the positive inotropic effect induced by either fluprostenol or phenylephrine (Figure 5A, data not shown for phenylephrine) in agreement with previous data.10,12

4. Discussion

These data indicate that FPR stimulation evokes a robust positive inotropic effect in rat left ventricle through increasing the phosphorylation level of MLC-2. Both MLCK and MLCP are involved in the FPR-mediated increase of MLC-2 phosphorylation. FPR stimulation increases phosphorylation of MYPT-2 by activating ROCK, decreasing MLCP activity. We propose that the FPR increases myofilament sensitivity to Ca2+ through enhancing MLC-2 phosphorylation, analogous to that proposed for the α1-AR and endothelin receptors in normal myocardium10,13 and the 5-HT2A receptors in failing myocardium.12 This study did not support a role for the Gq/11-coupled second messenger IP3 or PKC in regulating the phosphorylation of MLC-2.

FPR stimulation elicits an inotropic response qualitatively similar to that of α1-AR, composed first of a relatively fast transient negative followed by a sustained positive effect (Figure 1). The FPR-mediated inotropic response develops relatively slowly, and is characterized by a symmetrical change in the contraction–relaxation cycle with unchanged or slightly prolonged TPF and RT (Figure 1D), qualitative characteristics typical of cardiac Gq-coupled receptors.

The MLCK inhibitor ML-925 selectively inhibits cAMP-independent inotropic effects in heart tissue10,12 indicating that these effects are mediated via increased MLC-2 phosphorylation. In the present study, the ventricular FPR-mediated
Prostanoid F receptor inotropic effect

The FPR couples to Gq and FPR activation increases the formation of IP3 and DAG in rat ventricle, the latter activating most PKC isozymes. In this study, the FPR- and α1-AR-mediated inotropic effects were not reduced by inhibition of DAG-activation of most PKC isozymes using the non-subtype selective PKC inhibitor BIM. These data do not support a role for PKC in either the FPR- or α1-AR-mediated positive inotropic effect. The latter finding is in agreement with the study of Andersen et al. and both findings correspond to that reported at the 5-HT2A receptor. However, in mouse atrium, inhibition of PKCε enhanced Gq-coupled α1-AR responses. In contrast, the transient negative inotropic effect induced by both fluprostenol and phenylephrine was abolished by PKC inactivation with BIM. These data are in agreement with the observed PKC-dependent α1-AR and 5-HT2A receptor-mediated negative inotropic response in rat myocardium. BIM also increased basal contractility by 52 ± 5% (n = 22) 20–30 min after administration (data not shown), consistent with reports indicating that PKCα mediates a negative inotropic effect in the heart. Furthermore, both fluprostenol- and phenylephrine- induced inotropic effects were of a similar magnitude in the absence or presence of BIM, despite the large increase in basal contractility, highlighting the dissociation of the effect of PKC inhibition upon basal contractility as opposed to the FPR-mediated positive inotropic effect.

It seems unlikely that IP3 plays a pronounced role in both the FPR- and α1-AR-mediated inotropic effects, since the magnitude of inhibition by blockade of the IP3 receptor was modest and significantly less than that observed by inhibition of either MLCK or ROCK (Figures 4 and 5). The effects of 2-APB are difficult to explain since IP3 receptors are not present in the sarcolemma or in the sarcoplasmic reticulum in rat ventricular cardiomyocytes. In contrast, IP3 receptors are localized to the junctional sarcoplasmic reticulum in rat atrial myocytes and may participate in arrhythmogenesis. Possibly, the modest effect of 2-APB in the present study could result from inhibition of IP3 receptors residing in the nuclear envelope, known to connect with the sarcoplasmic reticulum. Since increasing the dose of 2-APB from 2 to 20 μM did not produce an expected further rightward shift in the fluprostenol concentration-response curve (Figure 5B), the effect of 2-APB is more likely a non-specific effect upon contractility, possibly through an inhibitory effect on store-operated Ca2+ channels.

Taken together, our data indicate that the signal transduction pathway underlying the FPR-mediated inotropic effect likely extends beyond the classical pathway established for Gα11-coupled receptors. Recently, it has been shown that G12/13 can activate ROCK through the signaling pathway of leukaemia-associated Rho guanine nucleotide exchange factor (LARG) activation of Rho. In vascular smooth muscle cells, the Gα12/13-coupled endothelin and angiotensin receptors also couple to G12/13, inducing cell contraction in a Rho/ROCK-dependent manner. It remains to be determined how FPR activation of Gαq modulates ROCK and MLCK activity or whether the FPR also initiates downstream signalling by coupling to G12/13.

There is increasing evidence that the RhoA/ROCK pathway is involved in agonist induced inotropic effects. In the present study, the FPR-mediated inotropic effect was significantly attenuated by Y-27632, a selective ROCK inhibitor, when added prior to or during the steady-state response to fluprostenol. Furthermore, Y-27632 reduced the fluprostenol-stimulated increase in MLC-2 phosphorylation by ~26%, a value corresponding with the modest reduction (~18%) of FPR-mediated MYPT-2 phosphorylation (Figure 4E). As expected, MYPT-2 phosphorylation was not reduced by blockade of CaM by W-7, consistent with its reported specificity for CaM.

There is increasing evidence that the RhoA/ROCK pathway is involved in agonist induced inotropic effects. In the present study, the FPR-mediated inotropic effect was significantly attenuated by Y-27632, a selective ROCK inhibitor, when added prior to or during the steady-state response to fluprostenol. Furthermore, Y-27632 reduced the fluprostenol-stimulated increase in MLC-2 phosphorylation by ~26%, a value corresponding with the modest reduction (~18%) of FPR-mediated MYPT-2 phosphorylation (Figure 4E). As expected, MYPT-2 phosphorylation was not reduced by blockade of CaM by W-7, consistent with its reported specificity for CaM.

There is increasing evidence that the RhoA/ROCK pathway is involved in agonist induced inotropic effects. In the present study, the FPR-mediated inotropic effect was significantly attenuated by Y-27632, a selective ROCK inhibitor, when added prior to or during the steady-state response to fluprostenol. Furthermore, Y-27632 reduced the fluprostenol-stimulated increase in MLC-2 phosphorylation by ~26%, a value corresponding with the modest reduction (~18%) of FPR-mediated MYPT-2 phosphorylation (Figure 4E). As expected, MYPT-2 phosphorylation was not reduced by blockade of CaM by W-7, consistent with its reported specificity for CaM.


